Opinion|Videos|December 16, 2025
Insurance Coverage and Patient Education
Experts discuss dose reduction strategies and emerging therapies for desmoid tumors, emphasizing patient monitoring and quality of life improvements.
Advertisement
Episodes in this series
Panelists discuss the questions below in this video.
- From your experience, what has insurance coverage been like for the pharmacotherapies used to treat desmoid tumors? Why might a step through with tyrosine kinase inhibitors before nirogacestat not be beneficial for patients? How do you educate patients about desmoid tumors and are there any resources that you find useful?
Advertisement
Related to this article
A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term benefits remain unproven.
Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.
SIRVA was rare after COVID-19 and flu shots, but COVID-19 vaccination had about 7 more cases per 100,000 doses in a study of 1.8 million.
Mucus plugs on chest CT may signal higher COPD hospitalization and death risk even without cough, and early data suggest they can be treated.
Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
COPD’s Old Narrative Is Outdated, GOLD Leaders Say in 2027 Update
3
EEOC Reportedly Plans to Narrow Pregnancy Accommodation Rules
4
Data Show Upadacitinib Repigments Skin in Nonsegmental Vitiligo
5